M. Neubauer

481 total citations
20 papers, 304 citations indexed

About

M. Neubauer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, M. Neubauer has authored 20 papers receiving a total of 304 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 4 papers in Pathology and Forensic Medicine. Recurrent topics in M. Neubauer's work include Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Research Studies (8 papers) and Lung Cancer Diagnosis and Treatment (5 papers). M. Neubauer is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Research Studies (8 papers) and Lung Cancer Diagnosis and Treatment (5 papers). M. Neubauer collaborates with scholars based in United States, Austria and Switzerland. M. Neubauer's co-authors include Nasser H. Hanna, Ramaswamy Govindan, Rafat Ansari, Daniel Bruetman, William B. Fisher, Paul Swanson, W G Harker, Howard A. Burris, Jordan Berlin and J. Randolph Hecht and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.

In The Last Decade

M. Neubauer

18 papers receiving 300 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Neubauer United States	10	196	182	47	31	30	20	304
Haruhito Kamei Japan	9	389 2.0×	465 2.6×	37 0.8×	66 2.1×	32 1.1×	37	573
Timothy D. Smile United States	11	150 0.8×	132 0.7×	17 0.4×	56 1.8×	41 1.4×	39	329
Caron Modeas United States	9	190 1.0×	355 2.0×	16 0.3×	28 0.9×	29 1.0×	12	399
Antonio Stefanelli Italy	9	102 0.5×	130 0.7×	16 0.3×	46 1.5×	64 2.1×	38	287
M. Benchalal France	8	94 0.5×	69 0.4×	24 0.5×	49 1.6×	18 0.6×	20	178
Céline Ségura‐Ferlay France	6	158 0.8×	180 1.0×	18 0.4×	48 1.5×	16 0.5×	10	276
Peter Farha United States	9	340 1.7×	272 1.5×	18 0.4×	43 1.4×	24 0.8×	15	442
Catherine Dubos‐Arvis France	8	310 1.6×	348 1.9×	50 1.1×	36 1.2×	104 3.5×	11	476
Croix C. Fossum United States	8	262 1.3×	82 0.5×	52 1.1×	61 2.0×	27 0.9×	14	414

Countries citing papers authored by M. Neubauer

Since Specialization

Citations

This map shows the geographic impact of M. Neubauer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Neubauer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Neubauer more than expected).

Fields of papers citing papers by M. Neubauer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Neubauer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Neubauer. The network helps show where M. Neubauer may publish in the future.

Co-authorship network of co-authors of M. Neubauer

This figure shows the co-authorship network connecting the top 25 collaborators of M. Neubauer. A scholar is included among the top collaborators of M. Neubauer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Neubauer. M. Neubauer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Neubauer, M., et al.. (2025). Mismatch Between Preoperative MRI Findings and Postoperative Histological Results in the Treatment of Tenosynovial Giant Cell Tumor. Anticancer Research. 45(3). 1087–1096.

Neubauer, M., Guillaume Nicolas, Andreas Bauman, et al.. (2023). Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study. European Journal of Nuclear Medicine and Molecular Imaging. 51(4). 1185–1193. 18 indexed citations

Jotte, Robert M., Alexander I. Spira, David Waterhouse, et al.. (2021). P60.13 MYLUNG Consortium: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network. Pragmatic Prospective RWR Study. Journal of Thoracic Oncology. 16(10). S1170–S1171.

Jalal, Shadia I., A. Melnyk, Donald Richards, et al.. (2011). Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology. Annals of Oncology. 23(7). 1730–1738. 58 indexed citations

Galsky, Matt D., Daniel D. Von Hoff, M. Neubauer, et al.. (2009). Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. Journal of Clinical Oncology. 27(15_suppl). 3541–3541. 10 indexed citations

Barriger, R. Bryan, Menggang Yu, Craig H. Reynolds, et al.. (2008). Rates and Risk of Pneumonitis in Non-small Cell Lung Carcinoma (NSCLC) Patients (pts) Treated with Concurrent Chemoradiation. International Journal of Radiation Oncology*Biology*Physics. 72(1). S117–S118. 2 indexed citations

Hanna, Nasser H., M. Neubauer, Rafat Ansari, et al.. (2007). Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01–24/USO-023. Journal of Clinical Oncology. 25(18_suppl). 7512–7512. 41 indexed citations

Neubauer, M., Rafat Ansari, Ramaswamy Govindan, et al.. (2007). An analysis of elderly patients (pts) treated on a phase III trial of cisplatin (P) plus etoposide (E) with concurrent radiotherapy (CRT) followed by docetaxel (D) vs observation (O) in pts with stage III non small cell lung cancer (NSCLC). Journal of Clinical Oncology. 25(18_suppl). 9037–9037. 6 indexed citations

Spira, Alexander I., Nicholas Iannotti, Michael A. Savin, et al.. (2007). Phase II study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 25(18_suppl). 7546–7546. 17 indexed citations

10.

Cox, John V., Thomas H. Cartwright, M. Neubauer, et al.. (2006). A Phase II study of gemcitabine plus zoledronic acid in subjects with Stage IV pancreatic cancer. Journal of Clinical Oncology. 24(18_suppl). 14002–14002. 2 indexed citations

11.

Berlin, Jordan, M. Neubauer, Paul Swanson, et al.. (2006). Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing ≥ 10% epidermal growth factor receptor (EGFr). Journal of Clinical Oncology. 24(18_suppl). 3548–3548. 55 indexed citations

12.

Neubauer, M., Rafat Ansari, Ramaswamy Govindan, et al.. (2006). Phase III study of cisplatin (P) plus etoposide (E) with concurrent chest radiation (XRT) followed by docetaxel (D) vs. observation in patients (pts) with stage III non-small cell lung cancer (NSCLC): An interim toxicity analysis of consolidation therapy. Journal of Clinical Oncology. 24(18_suppl). 7043–7043. 8 indexed citations

13.

Neubauer, M.. (2004). Results of a Phase II study of carboplatin plus gemcitabine in patients with untreated extensive small cell lung cancer. Lung Cancer. 46(3). 369–375. 8 indexed citations

14.

Bodkin, David, et al.. (2003). 806 Phase 2 study of first line chemotherapy using CT-2103 (XYOTAX) in patients with non-small-cell lung cancer who are > 69 years of age or who have performance status (PS) = 2. European Journal of Cancer Supplements. 1(5). S242–S242. 13 indexed citations

15.

Fridrik, Michael, Gerald Jäger, H. Kienzer, et al.. (1998). Efficacy and toxicity of 2-chlorodeoxyadenosine (cladribine)—2h infusion for 5 days—as first-line treatment for advanced low grade non-Hodgkin’s lymphoma. European Journal of Cancer. 34(10). 1560–1564. 20 indexed citations

16.

Fridrik, Michael, Richard Greil, H. Hausmaninger, et al.. (1997). Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin’s lymphoma (NHL). A multi- center trial by the Austrian Working Group For Medical Tumor Therapy. Annals of Hematology. 75(4). 135–140. 22 indexed citations

17.

Fridrik, Michael, H. Hausmaninger, Werner Linkesch, et al.. (1996). CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial.. Journal of Clinical Oncology. 14(1). 227–232. 9 indexed citations

18.

Dobnig, Harald, et al.. (1992). Successful treatment of primary adrenal insufficiency due to malignant non-Hodgkin's lymphoma. Journal of Molecular Medicine. 70(10). 938–41. 11 indexed citations

19.

Fellbaum, C., Helmut Popper, Martin Lehnert, et al.. (1989). Synchronous pulmonary carcinoid tumour and non-Hodgkin's lymphoma: report of two cases.. Thorax. 44(6). 516–518. 3 indexed citations

20.

Neubauer, M., et al.. (1982). [Occurrence of malignant non-Hodgkin lymphoma after long-term azathioprine therapy of chronic polyarthritis].. PubMed. 41(3). 73–5. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact